
Pharmacy practice notice: Transition to Nicovape® Q2 System Complete
Pharmacy Practice Notice Published on 9 January 2025 Transition to Nicovape® Q2 System...
Pharmacy Practice Notice Published on 9 January 2025 Transition to Nicovape® Q2 System...
Pharmacy Practice Notice Published on 22 November 2024 Scheduling of NVPs in Western...
Pharmacist Information Hub Understanding the current vaping laws Pharmacists have dispensed vaping products...
Pharmacist Information Hub The scientific consensus on vaping The gold standard for understanding...
Pharmacist Information Hub The role of therapeutic vaping in pharmacy Pharmacists are the...
Pharmacist Information Hub How to assess patients and supply S3 vapes Patients seeking...
Pharmacist Information Hub Checklist: Supplying S3 vapes Checklist: Supplying S3 vapes Step-by-step checklist...
Pharmacist Information Hub How to dispense S4 therapeutic vapes Understanding the prescribing pathways...
Pharmacist Information Hub How to file an SAS-C notification Log in to the...
Head of Medical Liaison
This website is a source of educational content for Australian-registered healthcare professionals only. You must not use the content for any other purpose. If you are a patient seeking medical advice please see your healthcare professional.
By accessing this website you are agreeing that you are an Australian-registered healthcare professional with a current AHPRA registration and are entitled to access this content. Your use of this content is also subject to our Terms of Use and Privacy Policy.
With low-concentration vapes becoming S3 from 1 October 2024, there is much confusion as to what is expected of pharmacists, and how the market is likely to play out.
Liber Pharmaceuticals has worked closely with thousands of pharmacists and prescribers for the last three years to ensure that you are able to supply therapeutic vapes effectively.
Join us as we share our thoughts on the following:
Each session will have at least 30 minutes for Q&A.